CRISAdVAC’s competitive advantage lies in its use of advanced CRISPR/Cas9 technology, offering highly targeted and effective protection against the FAdV-8b strain prevalent in Malaysia. Compared to conventional vaccines, it is more cost-effective at RM100 per 1,000 chickens, requires only a single dose, and can be administered either by injection or orally, reducing labour and operational demands. This combination of precision, affordability, and ease of use makes CRISAdVAC a superior and scalable solution for modern poultry farming.

‍

Outbreaks of Inclusion Body Hepatitis (IBH) caused by FAdV-8b infection continue to result in 2–30% mortality and significant financial losses among poultry farmers. Conventional vaccines require multiple doses and are costly, placing a burden on small and medium-scale farmers. Current vaccination methods also lack flexibility and demand skilled labour, posing challenges for large-scale poultry operations.

‍

CRISAdVAC is specifically developed to target the FAdV-8b strain using CRISPR/Cas9 technology, providing precise and effective protection against the strain found in Malaysia. It requires only a single dose at a lower cost of RM100 per 1,000 chickens, improving efficiency and reducing operational expenses. The vaccine can be administered either by injection or orally, enabling faster and more convenient vaccination across large-scale farms.

‍

The innovation lies in the development of CRISAdVAC, a CRISPR/Cas9-based vaccine specifically designed to combat the FAdV-8b strain causing Inclusion Body Hepatitis in chickens. It offers precise protection through advanced gene-editing technology, requires only a single low-cost dose, and allows flexible administration either by injection or orally, making it a more efficient and accessible solution for poultry farmers.

‍